A bladder-sparing approach for muscle-invasive bladder cancer

A bladder-sparing approach for muscle-invasive bladder cancer

VJOncology

1 year
194 Views
Share
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
From the 2018 Genitourinary Cancers Symposium, held in San Francisco, CA, Elizabeth Plimack, MD, from Fox Chase Cancer Center, Philadelphia, PA, introduces the key trials in progress at her center, including a treatment allocation study for patients with muscle-invasive localized bladder cancer, which features a combination of cystoscopy and tumour genomics to reduce the number of patients undergoing cystectomy. In addition, Dr Plimack also highlights a trial testing the combination of nivolumab and axitinib for kidney cancer (NCT03172754). Finally, she discusses a study looking to sensitize bladder cancer patients that are refractory to PD-1 inhibiton using guadecitabine (NCT03179943).
Up Next Autoplay
BOPA18__VJO_Rachel Elliott_01
BOPA18__VJO_Rachel Elliott_01
Category: Acute Lymphoblastic Leukemia
0 Views
VJOncology 1 year
New models for patient care: advanced pharmacy practitioners
New models for patient care: advanced pharmacy practitioners
Category: General
820 Views
VJOncology 1 year
Patient symptom and experience trackers
Patient symptom and experience trackers
Category: General
587 Views
VJOncology 1 year
Update from the Scottish Cancer Medicines Outcome Programme
Update from the Scottish Cancer Medicines Outcome Programme
Category: General
581 Views
VJOncology 1 year
The switch to biosimilar rituximab at UCH: 12 months on
The switch to biosimilar rituximab at UCH: 12 months on
Category: Lymphoma
562 Views
VJOncology 1 year
CPX-351: liposomal daunorubicin and cytarabine for treating high-risk AML
CPX-351: liposomal daunorubicin and cytarabine for treating high-risk AML
Category: General
368 Views
VJOncology 1 year
Visibility of Oncology Pharmacists to patients
Visibility of Oncology Pharmacists to patients
Category: Other
263 Views
VJOncology 1 year
Smart app to allow patients to manage their side effects independently
Smart app to allow patients to manage their side effects independently
Category: Breast Cancer
80 Views
VJOncology 1 year
cancer-druginteractions.org: a comprehensive tool for HCPs
cancer-druginteractions.org: a comprehensive tool for HCPs
Category: Other
39 Views
VJOncology 1 year
The emergence of mixed speciality oncology
The emergence of mixed speciality oncology
Category: Other
67 Views
VJOncology 1 year